BMRN

BioMarin's stock has been impacted by the acquisition of Amicus Therapeutics, expected to accelerate revenue growth but be slightly dilutive to full-year 2026 Non-GAAP Diluted EPS. The company raised its full-year 2026 revenue guidance. In February 2026, BioMarin reported its fourth-quarter and full-year 2025 results, including a GAAP Net Loss due to the withdrawal of Roctavian. The company's stock performance has seen a decline over the past 12 months. On May 4, 2026, BioMarin reported first-quarter 2026 financial results, with Q1 profit dropping as the Amicus acquisition ramps up, but sales beat estimates.